ALIBABA-CLOUD
3.11.2022 03:46:36 CET | Business Wire | Press release
Alibaba Cloud, the digital technology and intelligence backbone of Alibaba Group, started its annual Apsara Conference today by announcing the launch of ModelScope, an open-source Model-as-a-Service (MaaS) platform that comes with hundreds of AI models, including large pre-trained models for global developers and researchers. During its flagship conference, the global leading cloud provider also introduced a range of serverless database products and upgraded its integrated data analytics and intelligent computing platform to help customers further achieve business innovation through cloud technologies.
"Cloud computing has given rise to a fundamental revolution in the way computing resources are organized, produced and put to commercial use while shifting the paradigm of software development and speeding up the integration of the cloud and endpoint terminals," Jeff Zhang, President of Alibaba Cloud Intelligence, "As more customers are speeding up with their cloud adoption, we have been upgrading our cloud-based resources, services and tools to become serverless, more intelligent and digitalized in order to lower the barrier for companies to adopt new technology and capture more opportunities in the cloud era."
MaaS to create transparent and inclusive technology community
The ModelScope platform is today launched with over 300 ready-to-deploy AI models developed by Alibaba DAMO Academy ("DAMO"), Alibaba's global research initiative, in the past five years. These models cover various fields from computer vision to natural language processing (NLP) and audio. The platform also includes more than 150 state-of-the-art (SOTA) models, which are recognized globally as the best in their respective fields for achieving the results in a given task.
Also made available on the platform are Alibaba’s proprietary large pre-trained models such as Tongyi, which is capable of turning text into image with five billion parameters, and OFA (One-For-All), a six billion-parameter pre-trained model that excels at cross-modal tasks such as image captioning and visual question answering. Independent developers have also contributed dozens of models to the open-source platform to date.
As an open-source community, ModelScope aims to make developing and running AI models easier and more cost effective. Developers and researchers can simply test the models online for free and get the results of their tests within minutes. They can also develop customized AI application by fine-tuning existing models, and run the models online backed by Alibaba Cloud, or deploy them on other cloud platforms or in a local setting.
The launch underscores DAMO’s ongoing efforts and commitment to promote transparent and inclusive technology by reducing the threshold for building and running AI models, enabling universities and smaller companies to easily use AI for their research and in their business respectively. The community is expected to grow further with more quality models available on the platform from DAMO, partners from research institutes and third-party developers in the near future.
New and upgraded solutions to increase computing efficiency
Staying ahead of the emerging trend of serverless software development, Alibaba Cloud is making its key cloud products serverless to enable customers to concentrate on product deployment and development without worrying about managing servers and infrastructure. Essentially, Alibaba Cloud’s updated products focus on turning computing power into an on-demand capability for users.
Examples of these are the cloud native database PolarDB, the cloud-native data warehouse AnalyticDB (ADB) and ApsaraDB for Relational Database Service (RDS). Leveraging Alibaba Cloud’s serverless technologies, customers can enjoy automatic scaling with extreme elasticity based on actual workloads and a pay-as-you-go billing model to reduce costs. The automatic elastic scaling time on demands can be as little as one second. The use of updated database products can help businesses in the internet industry reduce their costs by 50%, on average, compared to using traditional ones. Currently, Alibaba Cloud has more than 20 serverless key products in total and is adding more product categories to become serverless.
Alibaba Cloud also upgraded its ODPS (Open Data Platform and Services), a self-developed integrated data analytics and intelligent computing platform, to provide companies with diversified data processing and analytics services. The platform can handle both online and offline data simultaneously in one system, providing businesses dealing with complex workloads with analytics for business decision-making with reduced cost and increased efficiency.
ODPS has refreshed global records for big data performance, according to recent results from the Transaction Processing Performance Council (TPC), an industry council that sets the standards for transaction processing and database benchmarking. Evaluated based on a 100 TB data benchmark, the performance of ODPS Maxcompute Cluster attained the top score for the sixth consecutive year. ODPS Hologres Cluster also shown a record-breaking result in the TPC-H 30000GB decision support benchmark test.
To drive workload collaboration between cloud and local hardware, Alibaba Cloud has announced the launch of the Wuying Architecture with a showcase on its applications on the Wuying Cloudbook. The Cloudbook with dedicated Architecture is designed to help users access unlimited computing power on the cloud in a more secure and agile manner while supporting collaboration and flexibility at a workplace.
About Alibaba Cloud
Established in 2009, Alibaba Cloud (www.alibabacloud.com) is the digital technology and intelligence backbone of Alibaba Group. It offers a complete suite of cloud services to customers worldwide, including elastic computing, database, storage, network virtualization services, large-scale computing, security, management and application services, big data analytics, a machine learning platform and IoT services. Alibaba maintained its position as the third leading public cloud IaaS service provider globally since 2018, according to IDC. Alibaba is the world’s third leading and Asia Pacific’s leading IaaS provider by revenue in U.S. dollars since 2018, according to Gartner.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221102006197/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom